Arcus Biosciences
RCUS
172 hedge funds and large institutions have $997M invested in Arcus Biosciences in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 61 increasing their positions, 59 reducing their positions, and 31 closing their positions.
68% more call options, than puts
Call options by funds: $5.35M | Put options by funds: $3.19M
3% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 59
2% less capital invested
Capital invested by funds: $1.02B → $997M (-$25.2M)
7% less funds holding
Funds holding: 185 → 172 (-13)
13.37% less ownership
Funds ownership: 71.53% → 58.16% (-13%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
39% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$31.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$11.5M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$9.47M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$35.7M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$9.85M |
| 3 |
Morgan Stanley
New York
|
-$9.13M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$7.5M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
-$6.78M |
RCUS Hedge Fund Activity: Q1 2024 in Review
172 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q1 2024, worth a combined $997M — down 2.5% from $1.02B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of RCUS and 19 opened new positions — a net loss of 12 holders — while 59 trimmed existing stakes and 61 added.
The largest buyer was Woodline Partners, adding an estimated $31.9M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $35.7M sold.
- 172 institutional investors held Arcus Biosciences (RCUS) as of Q1 2024, down from 185 in Q4 2023.
- Funds reported $997M of Arcus Biosciences stock for Q1 2024, down 2.5% quarter-over-quarter.
- 19 funds opened new Arcus Biosciences positions in Q1 2024 and 31 closed out, a net change of -12 holders.
- The largest Arcus Biosciences buyer in Q1 2024 was Woodline Partners, an estimated $31.9M added.
- The largest Arcus Biosciences seller in Q1 2024 was Octagon Capital Advisors, an estimated $35.7M sold.
Based on aggregated 13F filings for Q1 2024.